Royalty Pharma PLC
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Royalty Pharma PLC
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
/ 
Frequently asked questions
To buy Royalty Pharma PLC stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Royalty Pharma PLC by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Royalty Pharma PLC is RPRX:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Royalty Pharma PLC has its primary listing on NASDAQ. You can trade Royalty Pharma PLC with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Royalty Pharma PLC is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Royalty Pharma PLC as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Royalty Pharma PLC.